News

Ourobio takes top honors at Lighthouse Labs Demo Day

Clutching a plush shark, Alec Brewer, the co-founder and CEO of Ourobio, beamed Tuesday from the stage at the Byrd Theatre. The cuddly sea hunter marked his company as winner of a $1,500 cash prize for a “Shark Tank”-style competition at the the Lighthouse Labs Demo Day showcase.

“The cash is critical to us right now,” said Brewer. “We’ve remained entirely bootstrapped up until this point. Every dollar counts. So, we’re very appreciative of the cash prize.”

Ourobio, previously known as Transfoam, is a Charlottesville company that uses engineered microorganisms to turn industrial byproducts into a low-footprint, bio-based polymer. Put more simply, the company takes industrial waste and turns it into a biodegradable plastic-like substance. It is focusing on making the spools used in the consumer 3D printing filament space, but Ourobio’s founders have an eye on consumer food service products manufacturing

Ourobio co-founders Alec Brewer, left, and Kobe Rogers pose with their prize shark at the Lighthouse Labsl Demo Day.

“This plastic uniquely is not only degradable in the soil and dirt, but also degradable in the ocean,” said Brewer. “A lot of biodegradable plastics are incapable of degrading in the ocean. That’s something that sets our specific material apart from the rest and is a very important material for our future.”

Brewer thought the symbolism of the shark prize was fitting considering the company, which grew out of coursework at the University of Virginia, centers on marine sustainability and reducing waste in the ocean and environment. Kobe Rogers, Ourobio’s COO, and Simonne Guenette, the chief technology officer, are the other co-founders. The company is pre-revenue and is in a pre-seed stage.

Brewer was one of nine founders to present at the two-hour event, an annual demonstration for the Lighthouse Labs accelerator and the first to be held in person for two years because of the Covid-19 pandemic.

Joy Polefrone, health innovation consultant for Virginia Commonwealth University Health and one of four judges for the competition, said Ourobio won because Brewer’s pitch was very well defined and set a course for how the company was planning to move forward, articulating both sides of its market — the supplier side and how it was going to scale.

“It’s incredibly technically complicated, and they understand the technical complications of building plastics solutions, as well as the technical complications of creating something from a microbe,” said Polefrone.

The eight other companies at the pitch competition made up the rest of the Lighthouse Labs’ spring 2022 accelerator cohort, all of whom benefitted from a $20,000 equity-free investment.

Read more here.

Recent News

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and

09/14/2026

BRAINBox Solutions Announces Agreement with Prolight Diagnostics for Commercial Supply of Pyros® Devices for Delivery of BRAINBox Concussion Diagnostics/Prognostics at Point-of-Care

BRAINBox Solutions announced it has entered into an agreement with Prolight Diagnostics to supply its Psyros® instruments and cartridges for use in point-of-care (PoC) delivery of BRAINBox’s TBI diagnostic/prognostic tests for concussion (also known as mTBI or Acute Traumatic Encephalopathy). “This agreement is an important step towards commercialization of our solutions and reflects the successful